气体填充预防糖尿病玻璃体切除术后玻璃体出血:一项随机临床试验
该随机临床试验纳入因非清除性玻璃体出血行睫状体平坦部玻璃体切除术的增殖性糖尿病视网膜病变患者,比较20%至30%六氟化硫(SF6)气体填充与平衡盐溶液(BSS)填充。6个月随访时,SF6组术后玻璃体出血发生率为11.1%,BSS组为33.3%(P=0.008);两组最佳矫正视力无显著差异(P=0.58)。作者认为SF6气体填充可降低术后玻璃体出血发生率。
要点
- SF6组术后玻璃体出血6/54例(11.1%),BSS组14/42例(33.3%),P=0.008。
- 因术后玻璃体出血行非计划玻璃体切除术SF6组2/54例(3.7%),BSS组6/42例(14.2%),P=0.06。
- 6个月时两组平均最佳矫正视力无显著差异(P=0.58)。
核心结论
- 该试验表明,在因非清除性玻璃体出血行玻璃体切除术的增殖性糖尿病视网膜病变患者中,与BSS相比,SF6气体填充在6个月随访时降低了术后玻璃体出血的发生率。
- 作者认为,专科医生可考虑在玻璃体切除术中采用SF6气体填充,以帮助减少该患者人群的术后玻璃体出血。
研究设计与样本
- 前瞻性随机临床试验,纳入144例因非清除性玻璃体出血需行睫状体平坦部玻璃体切除术的增殖性糖尿病视网膜病变受试者。
- 受试者随机分入两组:A组行20%至30% SF6气体填充,B组行BSS玻璃体替代。
- 96例受试者完成随机化并完成6个月随访。
主要发现
- 试验期间术后玻璃体出血:A组(SF6)54例中6例(11.1%),B组(BSS)42例中14例(33.3%),P=0.008。
- 试验期间因术后玻璃体出血行非计划玻璃体切除术:A组54例中2例(3.7%),B组42例中6例(14.2%),P=0.06。
- 6个月随访时两组平均最佳矫正视力无显著差异(P=0.58)。
临床怎么用
- 作者认为,专科医生可考虑在因非清除性玻璃体出血行玻璃体切除术的增殖性糖尿病视网膜病变患者中采用SF6气体填充,以帮助减少术后玻璃体出血。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To compare vitreous substitution with sulfur hexafluoride (SF6) gas to balanced salt solution (BSS) for the prevention of postoperative vitreous hemorrhage (VH) in proliferative diabetic retinopathy (PDR) patients undergoing pars plana vitrectomy (PPV) for the indication of non-clearing VH. METHODS: One hundred forty-four PDR subjects requiring PPV for the indication of non-clearing VH were enrolled into the trial. Subjects were prospectively randomized into 1 of 2 vitreous substitution groups: Group A subjects underwent 20% to 30% SF6 gas tamponade, whereas Group B subjects underwent vitreous substitution with BSS. The primary outcome was the incidence of postoperative VH during the 6-month trial period. Secondary outcomes were unplanned PPV for VH and best corrected visual acuity (BCVA) at 6-months follow-up. RESULTS: Ninety-six subjects underwent randomization and completed 6-months follow-up. Postoperative VH during the trial period occurred in 6 of 54 subjects in Group A (SF6) (11.1%) and 14 of 42 in Group B (BSS) (33.3%) (P = .008). Unplanned PPV during the trial period for postoperative VH occurred in 2 of 54 in Group A (3.7%) and 6 of 42 in Group B (14.2%) (P = .06). The mean BCVA was not significantly different at 6-months follow-up between groups (P = .58). CONCLUSIONS: This trial indicates that vitreous substitution with SF6 gas lowers the incidence of postoperative VH compared with BSS in PDR subjects undergoing PPV for the indication of non-clearing VH at 6-months follow-up. Specialists may consider SF6 gas tamponade during PPV as a means of helping reduce postoperative VH in this patient population. NOTE: Publication of this article is sponsored by the American Ophthalmological Society.
引用
- Rush RB, Velazquez JC, Rosales CR, et al. Gas Tamponade for the Prevention of Postoperative Vitreous Hemorrhaging After Diabetic Vitrectomy: A Randomized Clinical Trial. Am J Ophthalmol. 2022. PMID: 35764103. doi:10.1016/j.ajo.2022.06.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。